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ABSTRACT
Hepatocyte nuclear factor (HNF)-1a is one of the
liver-enriched transcription factors involved in
many tissue-specific expressions of hepatic genes.
The molecular mechanisms for determining HNF1a-
mediated transactivation have not been explained
fully. To identify unknown proteins that interact
with HNF1a, we developed a co-IP-MS strategy to
search HNF1a interactions, and high mobility group
protein-B1 (HMGB1), a chromosomal protein, was
identified as a novel HNF1a-interacting protein.
In vitro glutathione S-transferase pull-down and
in vivo co-immunoprecipitation studies confirmed
an interaction between HMGB1 and HNF1a. The
protein–protein interaction was mediated
through the HMG box domains of HMGB1 and the
homeodomain of HNF1a. Furthermore, electro-
phoretic mobility shift assay and chromatin-
immunoprecipitation assay demonstrated that
HMGB1 was recruited to endogenous HNF1a-
responsive promoters and enhanced HNF1a binding
to its cognate DNA sequences. Moreover, luciferase
reporter analyses showed that HMGB1 potentiated
the transcriptional activities of HNF1a in cultured
cells, and downregulation of HMGB1 by RNA inter-
ference specifically affected the HNF1a-dependent
gene expression in HepG2 cell. Taken together,
these findings raise the intriguing possibility that
HMGB1 is a new cofactor of HNF1a and participates
in HNF1a-mediated transcription regulation through
protein–protein interaction.
INTRODUCTION
The transcriptional factor hepatocyte nuclear factor
(HNF)-1a is an atypical homeodomain-containing protein
identiﬁed by binding to similar regulatory cis-elements
present in special genes (1–3). Binding sites for HNF1a
have been shown in the promoters or enhancers of
genes that express almost exclusively in liver, such as
albumin (ALB),  -fetoprotein (AFP), a-ﬁbrinogen (FGA),
a1-antitrypsin (A1AT), transthyretin (TTR) and aldolase B
(ALDOB) (3–6). HNF1a can also modulate transcription
indirectly through transcription factor networks, includ-
ing the HNF1a-mediated negative regulation of genes
activated by HNF4a, which means that HNF1a plays a
central role in the ﬁne tuning of hepatocyte-speciﬁc gene
expression via its indirect negative autoregulatory
mechanism (7). HNF1a expression was ﬁrst regarded as
a hepatocyte-speciﬁc transcriptional regulator; later its
expression was also found in kidney, intestine and
endocrine pancreas (1,2). Further studies revealed that
HNF1a played an important role in the transcriptional
activation of genes critical for their functions of these
tissues (8–11). Mutations in HNF1a gene have been
identiﬁed in patients with Maturity Onset Diabetes of the
Young (MODY3) (12). Moreover, it has been reported
that expression of an HNF1a-dominant negative mutant
linked to MODY3 led to an impaired function of
pancreatic b-cells (13,14). The loss of HNF1a has been
shown during renal carcinogenesis, which is usually
accompanied by dediﬀerentiation processes, including
the loss of tissue-speciﬁc gene expression (15).
HNF1a uses a POU-homeodomain sequence and a
myosin-like dimerization domain located at the amino
terminus of the protein to bind its DNA recognition
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HNF1a, which is special among the homeodomain-
containing proteins, distinguish it from other home-
odomain transcription factors. First, its DNA-binding
domain contains a 21-amino acid insertion between the
highly conserved a helices 2 and 3, which is not found in
any other homeodomains. Second, HNF1a binds to its
target genes as a dimmer and it dimerizes in absence of its
DNA recognition sequence (2). The C-terminal part of
HNF1a contains three regions that are necessary for
transcriptional activation (2). The ability of various
HNF1a domains to interact with multiple coactivators
allows the formation of a platform for recruitment of a
transcriptional complex, leading to a strong enhancement
of transcription. PCBD1 (its another name is DcoH) is a
dimerization cofactor of HNF1a, which selectively stabi-
lizes HNF1a homodimers and enhances HNF1a-mediated
transcriptional activity through making of a tetrameric
complex (17). HNF1a also can physically interact with
histone acetyltransferases (HATs), CREB-binding
protein (CBP), p300/CBP-associated factor (P/CAF),
SRC-1 and RAC3 (18). CBP/p300 interacts with both
the DNA-binding domain and the activation domain of
HNF1a while P/CAF, SRC-1 and RAC3 interacts with
the HNF1a activation domain (19). These results support
a model that involves the combined action of multiple
coactivators recruited by HNF1a, which activate tran-
scription by coupling nucleosome modiﬁcation and
recruitment of the general transcription machinery.
HNF1a also interacts with GATA5, Neurog3 and Cdx2,
and the interactions lead to a cooperative enhancement
of HNF1a-mediated activation of transcription (20–22).
A synergy between HNF4a and HNF1a has been reported
too (23). However, the molecular mechanisms for
determining HNF1a-mediated transactivation have not
been explained fully.
In this work, we identiﬁed the HNF1a-binding partners
by co-IP combined with mass spectrometry strategy and
found that HMGB1 functioned as a potential coactivator
of HNF1a through direct interaction between the
HMG box domain of HMGB1 and homeodomain of
HNF1a.
MATERIALS AND METHODS
Plasmid constructions
The human full-length HNF1a, HMGB1 and HMGA2
were ampliﬁed by polymerase chain reaction (PCR) from
the human liver cDNA and cloned into the pcDNA3.1/
Myc-HisB vector (Invitrogen, Carlsbad, CA, USA). The
HNF1a deletion constructs were generated through
ligation of PCR products ampliﬁed from the
pcDNA3.1-HNF1a. The various HNF1a constructs
were cloned into the pGEX4T2 vector (Amersham
Pharmacia, Piscataway, NJ) using indicated sites
(Supplementary Data 1). The HMGB1 deletion constructs
were generated by PCR cloning and inserted into
pcDNA3.1/Myc-HisB. For subcellular localization
assays, HMGB1 cDNA was cloned into pEGFP-N1
(Clontech, Palo Alto, CA). The sequences of primers
used in plasmid constructions are shown in
Supplementary Data 1.
The Renilla luciferase expression vector (pRL-TK) was
purchased from Promega (Madison, WI) and luciferase
reporter plasmid pGL3-AFP was kindly provided by
Dr Huang Ailong (Chongqing University of Medical
Sciences, China).
Co-immunoprecipitation
HepG2 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (Gibco/BRL, Rockville, MD) supplemented with
10% fetal bovine serum. After centrifugation and washing
with phosphate-buﬀered saline (PBS), the cell pellets were
resuspended and lyzed using Mammalian Protein
Extraction Reagent (Pierce, Rockford, IL) according to
the protocol.
Three milligrams proteins in 1ml of lysates were mixed
with 2mg of goat polyclonal antibodies against HNF1a
(C-19, Santa Cruz Biotechnology, Santa Cruz, CA) or
goat IgG (sc-2028, Santa Cruz Biotechnology) and
incubated 90min at 48C with gentle shaking, followed
by adsorption to protein G plus-agarose beads (sc-2002,
Santa Cruz Biotechnology). After four times of extensive
washing to remove nonspeciﬁc binding with NETN buﬀer
[20mmol/l Tris–HCl at pH 8.0, 1mmol/l EDTA, 0.5%
NP-40 and 150mmol/l NaCl supplemented with protease
inhibitor mixture (Roche Diagnostics, Rotkreuz,
Switzerland)], the complex was resuspended in SDS
sample buﬀer, separated by 10% SDS–polyacrylamide
gel electrophoresis (PAGE). For MS analysis, separated
protein bands in the SDS–PAGE gel were visualized by
Coomassie brilliant blue staining.
MSanalyses
Proteins eluted with 5% acetic acid were denatured,
reduced and subjected to tryptic digestion. Resulting
peptides were analyzed by microcapillary reverse-phase
chromatography electrospray (ESI) MS using an
LCQ mass spectrometer (ThermoFinnigan, San Jose,
CA) equipped with a combination C18 trap ESI-emitter-
microcapillary liquid chromatography column design.
Mass spectra were acquired via data-dependent ion
selection, which was achieved through automatic switch-
ing between single MS and MS/MS modes. Proteins were
identiﬁed from MS/MS spectra using a database search
engine called COMET to search against the latest versions
of National Cancer Institute human protein databases.
The resulting proteins were analyzed using Peptide
Prophet and Interact Programs and validated manually.
Reciprocal immunoprecipitation and western
blotting analysis
HepG2 cells were transfected with pcDNA3.1-HMGB1 or
the vector alone using VigoFect transfection reagent
(Vigorous Biotechnology, China). After 48h of transfec-
tion, cell extracts were immunoprecipitated with anti-Myc
antibodies (sc-40, Santa Cruz Biotechnology) at 48C for
2h, followed by adsorption to protein A/G plus-agarose
beads (sc-2003, Santa Cruz Biotechnology) at 48C over-
night. Bound materials were washed thoroughly four
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PAGE, immunoprecipitated proteins were transferred
onto polyvinylidene diﬂuoride membranes (Amersham
life science, Buckinghamshire, England) and probed with
various antibodies. The enhanced chemiluminescence
(ECL) system (Santa Cruz Biotechnology) was used for
detection.
Subcellular localization assays
For HMGB1 and HNF1a location, immunoﬂuorescence
was performed. HepG2 cells were seeded in 6-well plates,
cultured in DMEM supplemented with 10% fetal bovine
serum and transfected with GFP-HMGB1 and Myc-
HNF1a. 24h later, the cells were ﬁxed for 30min at room
temperature with 4% paraformaldehyde in PBS, perfo-
rated with 1% Triton X-100 in PBS for 15min, blocked
with 3% BSA in PBS for 2h, incubated with primary
antibody overnight at 48C and probed with secondary
antibody. Primary mouse monoclonal antibodies were
used with anti-Myc antibody at 1:50. Secondary anti-
bodies were used with TRITC-labeled anti-mouse anti-
body at 1:50.
Confocal imaging was performed using Zeiss 510
META system. The green ﬂuorescence was excited at
488nm with 505–530nm barrier ﬁlter and red ﬂuorescence
was simultaneously excited at 543nm with 560nm barrier
ﬁlter.
Generation ofrecombinant proteins and
GST pull-down assays
HNF1a1-189, HNF1a190-319 and HNF1a320-631
fragments were cloned in frame with the glutathione
S-transferase (GST) gene of pGEX4T2, respectively.
The resulting GST fusion proteins were expressed in
Escherichia coli BL21, induced by 0.1mM isopropyl-b-D-
thiogalactopyranoside (IPTG) and solubilized from bac-
teria in lysis buﬀer (1% Triton X-100 in PBS) by
sonication. After centrifugation at 12000r.p.m. for
15min at 48C, the supernatant was added to the
glutathione-Sepharose 4B beads (Amersham Biosciences,
Uppsala, Sweden) and mixed gently at 48C overnight.
After binding, the beads were washed four times in
cold PBS to remove nonspeciﬁc binding. GST,
GST-HNF1a1-189, GST-HNF1a190-319 and GST-
HNF1a320-631 fusion proteins, as judged by Coomassie
bright blue staining, were bound to glutathione-Sepharose
beads.
Myc-HMGB1FL protein, Myc-HMGB18-161 pro-
tein, Myc-HMGB18-77 protein, Myc-HMGB192-161
protein and Myc-HMGA2 protein were got from the
whole-cell lysis of HepG2 cells which were transfected
with indicated plasmids as shown in Figure 2C and D. The
cell lysis were treated with DNase I (TaKaRa Japan) for
30min at 378C to remove the genomic DNA contamina-
tion before mixed with GST fusion protein which
adsorbed to Sepharose beads. The binding reaction was
carried out overnight at 48C in 1ml binding buﬀer
(20mmol/l Tris–HCl at pH 8.0, 150mmol/l NaCl,
1mmol/l EDTA, 10% glycerol and 0.1% NP-40). After
thoroughly washing, speciﬁcally bound proteins were
subjected to 15% SDS–PAGE followed by western
blotting analysis.
siRNA transfection
The selected target sequence of HMGB1 was 50-AGACCT
GAGAATGTATCCCCAAA-30 on the 30 noncoding
region according to the previous description (24).
HMGB1 siRNA were as follows: 50-AGACCUGAGAA
UGUAUCCCCAAADdTdT-30 (sense strand), 50-UUUG
GGGAUACAUUCUCAGGUCUdTdT-30 (antisense
strand). HepG2 cells were grown in 6-well plates to 50%
conﬂuence and HMGB1 siRNA were transfected into
HepG2 cells at 100pmol/well with Vigofect reagent
according to the manufacturer’s protocol. The nonspeciﬁc
RNA duplexes were used in control experiments. Cells
were harvested after incubation for 48–72h, and then real-
time PCR and western blotting were performed to detect
silence eﬀect.
Reverse transcription and real-time PCR
Total RNA isolation and reverse-transcription were
applied according to the manufacturer’s protocol. The
cDNA was analyzed using real-time PCR according to the
instruction from the kit. In brief, real-time PCR was done
using Bio-Rad IQ
TM5 Multicolor Real-time PCR
Detection System (Bio-Rad Laboratories, Hercules, CA)
and SYBR Premix Ex Taq
TM (2 ) kit (TaKaRa, Japan).
The cycling conditions were as follows: 958C for 1min, 40
cycles of 10s at 958C, 30s at 558C and 30s at 728C. SYBR
Green ﬂuorescence was measured after each elongation
step. Speciﬁc primers for each gene were listed in
Supplementary Data 1. At the end of PCR, a melting
curve analysis was performed by gradually increasing the
temperature from 558Ct o9 5 8C to determine purity. PCR
was set up in triplicates and threshold cycle (Ct) values of
the target genes were normalized to the endogenous
control. Diﬀerential expression was calculated according
to the 2
 CT method.
Transfectionand luciferase assays
HepG2 cells were transfected with diﬀerent plasmids as
indicate. In each case, vector DNA was added as necessary
to achieve a constant amount of transfected DNA
(1.25mg). Cells were collected 36h later after transfection
and lyzed in 100ml1   passive lysis buﬀer (Promega).
Luciferase assays were carried out with 50ml lysate using
the dual-luciferase reporter assay system (Promega) in a
chemiluminescence analyzer (FB12 luminometer; Berthold
Detection Systems, Germany). Luciferase activities were
expressed as fold induction relative to values obtained
from control cells. The results represented the mean of at
least three independent transfection experiments, each
carried out in duplicate. Renilla luciferase activity was
used as an internal control for transfection eﬃciency.
Preparation ofnuclear extracts andelectrophoretic
mobility shift assays (EMSAs)
HepG2 cells were transfected with various amount of
pcDNA3.1-HMGB1FL or derivatives of HMGB1 and
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In each case, pcDNA3.1 was added as necessary to keep
the total amount of transfected plasmids ﬁxed. The DNA
probe was prepared by annealing two oligonucliotides
50-GCTATGCTGTTAATTATTGGCA-30 and 50-TGCC
AATAATTAACAGCATAGC- 30, which correspond to
both strands of HNF1a recognition consensus sequence in
the promoter of AFP (3,4), and labeling them with [g-
32P]
ATP by ﬁlling in the T4 polynucleotide kinase (Gel Shift
Assay System, Promega). Nuclear extracts (10mg) were
incubated with the binding buﬀer for 10min, followed
by incubation with 0.5ng of
32P-labeled DNA probe for
30min at room temperature. The DNA–protein com-
plexes were analyzed by electrophoresis on a 4%
polyacrylamide gel in 0.5 Tris–borate/ethylene diamine-
tetraacetic acid (EDTA) electrophoresis buﬀer at 300V
followed by autoradiography. For competition experi-
ments, extracts were preincubated with a 50-fold excess of
unlabeled double-stranded oligonucleotides. In supershift
assays, 2mg of antibodies against HNF1a (sc-6547X,
Santa Cruz Biotechnology) were added to the nuclear
extracts 30min before the addition of radiolabeled probes.
Chromatin-immunoprecipitation (ChIP) assays
In this assay, 10
7 HepG2 cells were lyzed with cell lysis
buﬀer (10mM Tris–HCl, pH 8.0; 10mM NaCl; 0.2%
NP-40) on ice for 10min, centrifuged at 2500r.p.m.
for 5min at 48C, resuspended in nuclear lysis buﬀer
(50mM Tris–HCl, pH 8.0; 10mM EDTA; 1% SDS),
vortexed three times, sonicated six times to shear
chromatin and centrifuged at 12000r.p.m. for 15min at
48C. The supernatant were collected as the whole-cell
extract (WCE).
Protein–DNA immunocomplexes were immunoprecipi-
tated with rabbit polyclonal antibodies against HNF1a
(sc-8986, Santa Cruz Biotechnology) or rabbit polyclonal
antibodies against HMGB1 (BC003378, Protein Tech
Group, IL) or rabbit IgG (sc-2027, Santa Cruz
Biotechnology). WCE measuring 100ml were incubated
with antibodies in 900ml ChIP dilution buﬀer (0.01%
SDS, 1.1% Triton-X 100, 1.2mM EDTA, 16.7mM Tris–
HCl, pH 8.0, 167mM NaCl), with protein A/G agarose
beads as an adsorbent. Resins were washed with serious
buﬀers containing various detergents and NaCl in
diﬀerent concentrations. Following elution, DNA frag-
ments were isolated and puriﬁed using phenol/chloroform.
PCR was conducted using primers AFP-F (–282): 50-GC
GAGATCTTCTGCAACTTAGGGACAA-30 and AFP-
R (+32): 50-GCGAAGCTTGTTATTGGCAGTGGTG
GA-30 under the following conditions: 28 cycles, 598C, 5U
Taq polymerase and 25pmol of each primer. Ampliﬁed
products were analyzed on 1.5% Tris–borate/EDTA-
agarose gels.
Statistical analysis
Statistical analysis was performed using the Student’s
t-test. P<0.05 was considered signiﬁcant. Data were
expressed as mean SEM.
RESULTS
IP-MS strategy allows theidentification ofnovel
HNF1a-binding partners
In an eﬀort to detect proteins interacting with HNF1a,w e
developed a co-IP-MS strategy to search HNF1a interac-
tions in vivo. HNF1a-containing protein complex was
immunoprecipitated from human hepatoma cell line
HepG2 cells using HNF1a antibody and HNF1a in
the immunoprecipitation complex was identiﬁed by
western blotting (data not shown). To determine whether
containing reported interactors of HNF1a in the
HNF1a-containing protein complex, HNF4, an admitted
cofactor of HNF1a, was veriﬁed in the HNF1a–IP
complex by western blotting (data not shown). Then,
protein complexes were separated by SDS–PAGE, and
stained with Coomassie bright blue (Supplementary Data
2). Diﬀerential blue color bands were excised, trypsinized
and analyzed through microcapillary liquid chromatogra-
phy MS/MS followed by protein database searching of the
generated spectra. We set up the criteria for a minimum
two unique peptides per positive protein identiﬁcation,
and we reported only those proteins that were identiﬁed
in at least two independent experiments. After performing
MS/MS, a total of 18 nonredundant proteins were found
to interact with HNF1a compared to the control
(Table 1). To conﬁrm the novel interactors of HNF1a,
we selected four of the novel HNF1a-binding partners
(RANBP1, 14-3-3zeta, CBX3, HMGB1) for half-in vivo
co-immunoprecipitation in HepG2 cells. Immunoblotting
analysis showed that HNF1a were co-immunoprecipitated
with all four proteins (data not shown). These results
indicate that the IP-MS strategy in our study could be
eﬀective.
Identification ofHMGB1 interacting withHNF1ain vivo
To assess the intracellular association of HNF1a with
HMGB1, a half-in vivo co-immunoprecipitation was
performed. HepG2 cells were transfected with
pcDNA3.1-HMGB1 or pcDNA3.1/Myc-HisB, and then
the cell lysates were subjected to immunoprecipitation
with anti-Myc antibody and western blotting with
anti-HNF1a antibody. Immunoblotting analysis showed
that HNF1a was co-immunoprecipitated with HMGB1
(Figure 1A and B). To further conﬁrm this association,
colocalization of HNF1a and HMGB1 was studied.
As shown in Figure 1C, HNF1a and HMGB1 showed
colocalization when the images were merged. These results
indicate that HMGB1 interacts speciﬁcally with HNF1a
in vivo.
Mapping the bindingsite of HNF1aand HMGB1
To map the domain of HNF1a protein required for
interaction with HMGB1, we performed GST pull-down
assay using GST fusion proteins containing deletion
mutants of HNF1a with HMGB1 or HMGA2, which
is another nonhistone chromosomal high mobility
group (HMG) protein family member and was regarded
as irrelevant negative control. HNF1a consists of several
domains such as dimerization, homeobox and
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various fragment of HNF1a was constructed into
pGEX4T2. GST and GST fusion proteins were expressed
in E. coli BL21 and puriﬁed using glutathione-Sepharose
beads according to the manufacturer’s instructions, as
judged by Coomassie bright blue staining (Figure 2B).
Myc-HMGB1FL was pulled down with GST-
HNF1a190-319 whereas not with those with amino
acid residues 1–189 or 320–631 (Figure 2C). These ﬁndings
demonstrate that fragment 190–319aa of HNF1a, con-
taining the homeobox domain is responsible for the
interaction with HMGB1. All derivatives of HNF1a did
not pull down with HMGA2, which suggested the speciﬁc
interaction between HNF1a and HMGB1 (Figure 2C).
To map the domain of HMGB1 protein required
for interaction with HNF1a, we performed another GST
pull-down assay. HMGB1 is structured into two
HMG box domains plus a highly acidic C-terminal
region (Figure 2D). We therefore generated the following
four Myc-tagged proteins: full-length HMGB1,
HMGB18-161, HMGB18-77 and HMGB192-161.
As expected, HMGB1FL exhibited speciﬁc binding to
HNF1a190-319 (Figure 2D). It was further revealed that
HMGB18-161, HMGB18-77 and HMGB192-161
were capable of binding (Figure 2D), indicating that a
single HMG box was suﬃcient for the interaction and that
the acidic tail was not required. Together, these results
suggest that the HMG box of HMGB1 and the homeobox
domain of HNF1a are necessary for the interaction
between HNF1a and HMGB1.
HMGB1 enhances HNF1a-mediated transactivation
The existence of functional interaction between
HNF1a and HMGB1 was analyzed in cell culture
C
Figure 1. Analysis of interaction between HNF1a and HMGB1.
HepG2 cells were transfected with pcDNA3.1-HMGB1 or
pcDNA3.1-Myc/HisB, and after 48h, cell lysates were prepared and
immunoprecipitations were performed with anti-Myc antibody.
Immunoprecipitates were analyzed with anti-Myc antibody (A) and
anti-HNF1a antibody (B). The positions of HMGB1, HNF1a and the
IgG were indicated by an arrow. (C) HepG2 cells were co-transfected
with GFP-HMGB1 and Myc-HNF1a for 24h. Immunoﬂuorescence
staining was performed with anti-Myc monoclonal antibody to analyze
the localization of HNF1a. The locations of HMGB1 (green)
and HNF1a (red) were observed through confocal imaging. Scale
bar: 10mm.
Table 1. List of proteins identiﬁed in co-immunoprecipitated HNF1a
complex by MS/MS
Gene name Protein description Number of
unique
peptides
ACTB Actin, beta 2
ANXA2 Annexin a2 4
CBX3 Chromobox protein homolog 3 2
HIST2H2AB Histone 2, h2ab 2
HMGB1 High mobility group protein b1 3
IGFBP7 Insulin-like growth factor binding
protein 7
2
RPSAP15 Ribosomal protein SA pseudogene 15 5
LDHA Lactate dehydrogenase a 2
PEBP1 Phosphatidylethanolamine-binding
protein
2
RANBP1 Ran-binding protein 1 3
SFRS7 Splicing factor, arginine/serine-rich 7,
35kda
2
SNX14 Sorting nexin 14 2
VCP Valosin-containing protein 2
VIM Vimentin 13
YWHAB Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
beta polypeptide
3
YWHAE Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
epsilon polypeptide
3
YWHAG Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
gamma polypeptide
3
YWHAZ Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
zeta polypeptide
3
HNF1a Hepatocyte nuclear factor 1a 3
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moter region of AFP included several binding sites for
HNF1a protein, and HNF1a gene product activated
transcription of AFP-reporter gene in transient
co-transfection assays. In a typical experiment, HNF1a,
expressed from the CMV promoter-driven construct,
activated transcription of pGL3-AFP reporter 73-fold
over the basal level (Figure 3, P<0.05), and HMGB1 by
itself showed little eﬀect on the transcription activity of the
pGL3-AFP reporter. However, co-transfection of HNF1a
together with HMGB1 expression construct led to a
strong stimulation of the reporter activity, up to 187-fold
over the basal level (Figure 3, P<0.05) and to 2–3-fold
over the maximum level obtained with HNF1a alone.
Co-transfection of HNF1a with HMGB18-161 stimu-
lated the reporter activity up to 140-fold over the basal
level (Figure 3, P<0.05). Co-transfection of HNF1a with
HMGB192-161 activated the reporter activity up to 170-
fold over the basal level (Figure 3, P<0.05). However,
only little eﬀect was shown on the transcription activity of
the pGL3-AFP reporter when HNF1a co-transfected with
HMGB18-77 (Figure 3, P<0.05). These functional
studies demonstrate that HMGB1 potentiates the tran-
scriptional activities of HNF1a and suggest a functional
interaction that exist between HNF1a and the second
HMG box domain (HMGB192-161) of HMGB1.
HMGB1 facilitates the bindingof HNF1a
to its targetsequences
To understand the mechanism of enhancement of HNF1a
activity by HMGB1, we examined the eﬀect of HMGB1
on the DNA-binding ability of HNF1a. EMSA with
nuclear extracts from HepG2 cells which were transfected
with pcDNA3.1-HMGB1FL or derivatives of HMGB1
and the
32P-labeled fragment of DNA covering the  138/
 119 AFP promoter sequence was performed. As shown
in Figure 4A, speciﬁc DNA–protein complexes were
reproducible detected. When HMGB1 was added, the
intensities of bands enhanced in a dose-dependent
manner, indicating that HMGB1 stimulated HNF1a
binding to the  138/ 119 AFP promoter region (lanes
2–6 in Figure 4A). It was also remarkable that
pcDNA3.1-HMGB1FL did not change the mobility,
suggesting that HMGB1 was not included in the
A
B
C
D
Figure 2. Mapping the binding site of HNF1a and HMGB1.
(A) Schematic representation of domain structure of HNF1a.( B)
GST, GST-HNF1a1-189, GST-HNF1a190-319 and GST-
HNF1a320-631 fusion proteins were expressed in E. coli, puriﬁed
by glutathione-Sepharose beads. The complexes were washed to remove
noninteracting proteins, electrophoresed in SDS–PAGE and visualized
by Coomassie bright blue staining. (C) Lysates of HepG2 cells that
were transfected with pcDNA3.1-HMGB1FL or pcDNA3.1-HMGA2
were incubated with the following fusion proteins, respectively,
including GST alone, GST-HNF1a1-189, GST-HNF1a190-319
and GST-HNF1a320-631. Whole-cell lyses were extracted and
digested with DNase I and performed GST pull down. Complexes
were detected by western blotting analysis using anti-Myc antibody. (D)
Schematic representation of domain structure of HMGB1 was shown.
HepG2 cells were transfected with pcDNA3.1-HMGB1FL, pcDNA3.1-
HMGB18-161, pcDNA3.1-HMGB18-77 or pcDNA3.1-
HMGB192-161, respectively. Twenty-four hours later, whole-cell
lyses were extracted and digested with DNase I and performed GST
pull-down. Cell lysates of pcDNA3.1-HMGB1FL were pulled down by
GST-HNF1a190-319 fusion protein and were not pulled down by
GST alone. Cell lysates of pcDNA3.1-HMGB18-161 were pulled
down by GST-HNF1a190-319 fusion protein and not pulled down by
GST alone. Cell lysates of pcDNA3.1-HMGB18-77 were pulled down
by GST-HNF1a190-319 fusion protein and not pulled down by GST
alone. Cell lysates of pcDNA3.1-HMGB192-161 were pulled down
by GST-HNF1a190-319 fusion protein and not pulled down by
GST alone.
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which HMGB1 domain donated to the enhancement, we
operated another EMSA. As shown in Figure 4C,
compared with control (pcDNA3.1, lane 3), the bands
intensities of HNF1a–DNA complex were enhanced by
addition of HMGB1FL (lane 2) and its derivatives,
containing the two HMG boxes (HMGB18-161,
lane 4), or HMG box B (HMGB192-161, lane 6).
Moreover, the addition of HMGB192-161 protein
resulted in an enhancement of HNF1a binding in a
dose-dependent manner (lanes 9–11). On the other hand,
HMGB18-77 could not increase HNF1a DNA-binding
ability (lane 5). Thus, HMGB192-161 (box B) played a
major role in promoting the formation of the HNF1a
protein–DNA complex. Competition experiments with an
excess of nonradioactive-labeled HNF1a recognition
sequence completely led to the disappearance of the
protein–DNA complexes (lane 7 in Figure 4A and C).
Supershift experiments were performed to identify
HNF1a, which was bound in the protein–DNA complexes
(lane 8 in Figure 4A and C). Western blotting analysis was
presented to reﬂect the amounts of HMGB1FL and
HMGB192-161 (Figure 4B and D) in reaction.
HMGB1 is recruited toendogenous AFP promoters
To precisely understand the interaction between HNF1a
and HMGB1, ChIP was used to determine whether
HMGB1 was recruited by HNF1a to the HNF1a-
dependent promoter in vivo. Previous studies showed that
HNF1a recognition sites located at the region from  132
to  118bp in AFP promoter (3,4,6). Following formalde-
hyde cross-linking and chromatin precipitation with
respective antibodies, the precipitated DNA was ampliﬁed
with speciﬁc primers (Supplementary Data 1). The
region from  282bp to +32bp upstream of AFP
promoter was enriched for HNF1a and HMGB1 binding.
Figure 4. HMGB1 enhanced HNF1a DNA-binding activity.
(A) HepG2 cells were transfected with various amounts of
HMGB1FL (lane 2: 4mg, lane 3: 3mg, lane 4 2mg, lane 5: 1mg and
lane 6: 0mg). Control vector was added as necessary to maintain the
amount of transfected plasmids constant. After 24h, nuclear extracts
were prepared to analysis the binding to
32P-labeled probe by
electrophoretic mobility shift assay (EMSA). The annealed oligonucleo-
tides contained the sequence between  138 and  119 of the AFP
promoter. The
32P-labeled oligonucleotides were incubated with the
indicated nuclear extracts and/or antibody and resolved on a 4%
polyacrylamide gel. Lanes 2–6 showed that increasing amounts of
HMGB1FL protein enhanced DNA binding of HNF1a in a dose-
dependent manner. The intensity quantity was measured by densito-
metry and the results were graphed as fold of changes compared with
control (pcDNA3.1, lane 6). (B) Western blotting was executed to
manifest the amount of HMGB1 in each reaction. (C) EMSA were
performed as described for (A), using nuclear extracts derived from
HepG2 cells which were transfected with 4mg various deletion
derivatives of HMGB1 (lane 2: HMGB1FL, lane 3: pcDNA3.1, lane
4: HMGB18-161, lane 5: HMGB18-77 and lane 6: HMGB192-
161). Lanes 9–11 showed that increasing amounts of HMGB192-161
protein enhanced DNA binding of HNF1a in a dose-dependent manner
(lane 9: 1mg, lane 10: 2mg, lane 11: 3mg). The intensity quantity was
measured by densitometry and the results were graphed as fold of
changes compared with control (pcDNA3.1, lane 3). Control vector
was added to keep the transfected plasmids amounts equal to 4mg.
(D) Western blotting was fulﬁlled to exhibit the amount of
HMGB192-161. Lane 1 in both (A) and (C) represented control
lanes in which the oligonucleotide probes were not incubated with any
nuclear extracts. Competition experiments were carried out with 50-fold
excess of unlabeled oligonucleotide [lane 7 in (A) and (C)]. For
supershift experiments, nuclear extracts were incubated with antibodies
speciﬁc for HNF1a [lane 8 in (A) and (C)].
Figure 3. HMGB1 enhanced HNF1a-mediated transcription. HepG2
cells were co-transfected with 400ng pGL3-AFP reporter vector, 20ng
HNF1a expression vector and 800ng HMGB1FL expression vector or
HMGB18-161 expression vector or HMGB18-77 expression vector
or HMGB192-161 expression vector or control vector, and then the
luciferase activity was measured (P<0.05). The results were shown as
the mean SEM of triplicate experiments.
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(Figure 5A). HNF1a immunoprecipitated complex and
HMGB1–IP complex were detected with western blotting
analysis using HNF1a and HMGB1 antibodies
(Figure 5B). We conclude that HMGB1 is speciﬁcally
recruited by HNF1a to the AFP promoter and responsible
for HNF1a-dependent transactivation.
RNA interference of HMGB1 leads to alteredexpression
ofHNF1atarget genes
To further conﬁrm the role for HMGB1 in the regulation
of HNF1a target genes in vivo, we performed RNA
interference assay to investigate whether the decrease of
HMGB1 expression altered expression of other known
HNF1a target genes. As Figure 6A and B, and Table 2
showed, transfection with siRNA directed against
HMGB1 into HepG2 cells reduced the level of HMGB1
protein by 70% (P<0.05). However, transfection with
nonspeciﬁc RNA only slightly decreased the level of
HMGB1 protein. The levels of HNF1a protein or b-actin
were not aﬀected by these siRNAs. As shown in
Figure 6C, when endogenous HMGB1 expression was
knocked down by RNAi, the activity of pGL3-AFP
reporter was reduced 60% in parallel (P<0.05).
Moreover, HMGB1 downregulation inhibited expression
of ALB, AFP, A1AT, FGA, PAH, GLUT2, LPK,
IGFBP1 and APOC3 genes (Figure 6D and Table 2,
P<0.05), which was consistent with previous observa-
tions that HNF1a positively regulated expression of these
genes (4–6,13–15). However, the HMGB1 downregulation
did not aﬀect expression of PEPCK genes (Figure 6D and
Table 2, P>0.05), which was regulated by the AREBP,
C/EBP and ATF-2 (26). These results indicate that
HMGB1 speciﬁcally modulates expression of HNF1a
target genes.
DISCUSSION
Protein–protein interactions are essential for HNF1a-
mediated transcription regulation. Studies on the muta-
tions in HNF1a, which result in MODY3, raise a
possibility that the in vivo protein–protein interaction is
a critical determinant of gene activation by HNF1a (27).
A few nuclear proteins that act as modulators of HNF1a-
regulated transcription have been identiﬁed (17–22).
However, the defects in gene regulation resulting from
the disruption of interaction between HNF1a and
its cofactors are largely unknown. In the present study,
we demonstrate that HMGB1 is a new cofactor of
HNF1a, which interacts with HNF1a, enhances its
binding to cognate DNA sequences and improves its
transcriptional activity.
HMGB1, historically known as an abundant, nonhis-
tone architectural chromosomal protein, is extremely
conserved across species (28). As a nuclear protein,
HMGB1 stabilizes nucleosomes and allows bending of
Figure 5. HNF1a and HMGB1 physically interacted and were recruited
to AFP promoter in vivo.( A) Speciﬁc recruitment of HMGB1 by
HNF1a by ChIP assays in HepG2 cells. Primers speciﬁc for the AFP
promoter ( 282bp to +32bp) were used to amplify the DNA
associated with HNF1a and HMGB1 in vivo.( B) Cleared whole-cell
extract was ﬁrst incubated with control IgG, anti-HNF1a or anti-
HMGB1 antibody, then with protein A/G agarose as an adsorbent.
Bound proteins were detected by immunoblotting with antibodies to
HNF1a or HMGB1.
Figure 4. Continued.
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been implicated in the regulation of transcription, via both
activation and repression. It has been documented that
HMGB1 interacted both with the basal transcription
machinery (29) and with individual transcription factors
such as Hox proteins, p53, NF-kB and steroid hormone
receptors (24,30–34). HMGB1 binds transiently to DNA,
prebends DNA into thermodynamically unfavorable
conformation and oﬀers DNA to the transcription
factor, which will eventually form a stable complex with
DNA. In our series of experiments, we found that the
homeodomain of HNF1a and HMG box of HMGB1 were
their interaction fragments. Previous reports on regulation
of HNF1a interactions with DNA have implicated its
homeodomain in Cdx2 positive regulating DNA binding
(21). Involvement of the homeodomain in both DNA
binding and protein–protein interaction also has been
observed, as in Pit-1–Oct interaction (35). It has been
documented that some Hox proteins, such as Oct protein,
TBP or steroid receptor, could interact with HMGB1
through either HMG box A (8–77aa) or HMG box B
(92–161aa) domain of HMGB1 (24,32,33). In the present
study, we also determined that HNF1a directly interacted
with box A and box B of HMGB1. Both HMG box A
and box B are HMGB1 DNA-binding domains.
Either box A or box B of HMGB1 enhanced the
HoxD9-mediated transactivation alone(33). In our stud-
ies, we found that HMGB1 enhanced HNF1a-mediated
transcription depended heavily on HMG box B of
HMGB1. Data from ChIP and EMSA demonstrated
that HMGB1 was recruited to endogenous HNF1a-
responsive promoters and increased the DNA-binding
activity of HNF1a. We then propose that HMGB1 might
be recruited by HNF1a protein and the physical contact
between the homeodomain and one HMG box directs
these two DNA-binding domains to adjacent or over-
lapping DNA segments, generating a complex, which
might contribute to the enhanced binding of HNF1a to its
targeting site. Moreover, a downregulation of HNF1a
target genes expression after knockdown of endogenous
HMGB1 with siRNAs strongly supports an important
role of HMGB1 as a physiological cofactor of HNF1a.
The diﬀerent extents of suppression by HMGB1 RNAi
knockdown on HNF1a targets may be due to diﬀerent
transcription regulation mechanism of target genes. For
example, the tissue speciﬁcity of ALB gene expression is
Figure 6. Suppression of HMGB1 decreases HNF1a-mediated tran-
scription. (A and B) HepG2 cells were transfected with HMGB1 siRNA
or nonspeciﬁc RNA duplex for 60h. HMGB1 expression was detected
by immunoblotting with b-actin as the internal control and real-time
PCR with GAPDH as the internal control. PCR was performed in
triplicates, and results were normalized to the endogenous control. Fold
induction represented the relative expression (P<0.05) of HMGB1.
The results were the mean   SEM of triplicate experiments. (C) HepG2
cells were co-transfected with 400ng pGL3-AFP and 20pmol
siHMGB1 or nonspeciﬁc RNA duplex, and then the luciferase activity
was measured (P<0.05). The results were shown as the mean SEM
of triplicate experiments. (D) Suppression of HMGB1 decreased the
expression of HNF1a target genes. Real-time PCR using primer sets
speciﬁc for ALB, AFP, A1AT, APOC3, FGA, GLUT2, LPK, IGFBP1,
PAH, PEPCK and GAPDH. GAPDH was used as the internal control.
HepG2 cells were seeded in 6-well plates and transfected with 100pmol
HMGB1 siRNA or nonspeciﬁc duplex for 60h. Total RNA were
extracted and reverse transcripted. PCR was performed in triplicates,
and results were normalized to the endogenous control. Fold induction
represented the relative expression (P<0.05) of ALB, AFP, A1AT,
APOC3, FGA, GLUT2, LPK, IGFBP1, PAH and PEPCK mRNA in
HMGB1 siRNA-treated HepG2 cells over that of nonspeciﬁc duplex-
treated controls. The results were the mean SEM of triplicate
experiments.
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CEBPA (36); IL-6-mediated IGFBP1 promoter activation
is via the intact HNF1-binding site and is dependent on
the presence of endogenous HNF1a and STAT3 and AP-1
(c-Fos/c-Jun) (37); HNF1a recruits p300 to transactive the
expression of GLUT2 gene (38).
Previous studies have shown that HMGB1 played an
important role in the regulation of lipogenic, cholestero-
genic and acute phase (AP) responsive genes transcription
(24). The responsibility of HNF1a in cholesterol home-
ostasis is important as well, in which HNF1a is a key
regulator of multiple pathways essential for the main-
tenance of normal plasma cholesterol levels, including bile
acid synthesis, bile acid uptake by the liver, intestines and
kidney, and HDL-cholesterol metabolism (39). It has been
documented that homozygous knockout mice of the
HMGB1 gene were born alive, but died within 24h due
to hypoglycemia (40). MODY-associated HNF4a muta-
tions caused increased insulin secretion in the fetal and
neonatal period, resulting in increased birthweight and
neonatal hypoglycemia (41). To some extent, HNF4a
mutation will produce the same result as HNF1a-
mediated negative regulation. Therefore, the phenotype
of Hmgb1
 /  mice provides evidence that the interaction
between HNF1a and HMGB1 should be critical for
HNF1a-dependent regulation. Supporting this, HMGB1
downregulation by RNA interference speciﬁcally aﬀected
the HNF1a-dependent gene expression in HepG2 cells.
Our present ﬁndings thus raise the possibility that
HMGB1 might be potentially involved in this dynamic
regulation of hepatic genes expression.
In summary, we have identiﬁed HMGB1 as a novel
interactor for HNF1a, which enhanced its binding to
cognate DNA sequences and transcriptional activity.
Investigation of this interaction between HMGB1 and
HNF1a protein will give valuable insights into yet
undiscovered roles of HMGB1 in the regulation of
transcription and hepatic function.
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